Colorectal Cancer


Latest News

gi cancer
First-Line Pembrolizumab Shows A Trend Towards Overall Survival in MSI-D/dMMR mCRC

December 2nd 2023

The median overall survival was 77.5 months with frontline pembrolizumab vs 36.7 months with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.

colon cancer
Using ctDNA MRD Monitoring During Active Metastatic CRC Treatment

November 22nd 2023

‘More Isn’t Always Better’ With Adjuvant Chemotherapy in Colon Cancer

November 17th 2023

FDA Approval
FDA Approves Fruquintinib for Patients With Pretreated Metastatic Colorectal Cancer

November 9th 2023

colorectal cancer
Opinion: For Those With Lynch Syndrome, Exercise May Be A Useful Defense Against Colorectal Cancer

October 24th 2023

The Vitals

More News

© 2023 MJH Life Sciences

All rights reserved.